The global Neurologic Disorders Therapeutics Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Indication (Multiple sclerosis, Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, Others), By DrugGlass, Immunomodulator, Interferons, Decarboxylase Inhibitors, Dopamine Agonists, Others), By Route of Administration (Oral, Injection, Transdermal).
The neurologic disorders therapeutics market in 2024 is witnessing robust growth driven by the increasing prevalence of neurological conditions such as epilepsy, migraine, multiple sclerosis, and neuropathic pain, as well as advancements in drug discovery and development. Neurologic disorders pose significant challenges in treatment due to their complex pathophysiology and heterogeneous clinical presentations. With the emergence of disease-modifying therapies, symptomatic treatments, and targeted interventions addressing specific molecular pathways, the treatment landscape for neurologic disorders is evolving. Market players are investing in research and development, clinical trials, and regulatory approvals to bring novel therapeutics to market and address the unmet medical needs of patients with neurological conditions, driving further growth and innovation in the market.
The global Neurologic Disorders Therapeutics Industry is highly competitive with a large number of companies focusing on niche market segments. Amidst intense competitive conditions, Neurologic Disorders Therapeutics Companies are investing in new product launches and strengthening distribution channels. Key companies operating in the Neurologic Disorders Therapeutics Industry include- AbbVie Inc, Acadia Pharmaceuticals Inc, Acorda Therapeutics Inc, Bayer AG, Biogen Inc, Eisai Co. Ltd, F. Hoffmann La Roche Ltd, GlaxoSmithKline Plc, H Lundbeck AS, Johnson and Johnson, Merck KGaA, Mylan NV, Novartis AG, Otsuka Holdings Co. Ltd, Pfizer Inc, Sanofi S.A., Takeda Pharmaceutical Co. Ltd, Teva Pharmaceutical Industries Ltd, UCB S.A., USWM LLC.
In the Neurologic Disorders Therapeutics market, a prominent trend is the advancements in targeted therapies. Traditional treatments for neurological disorders often have limited efficacy and may cause adverse side effects. With advances in neuroscience and molecular biology, there's a growing emphasis on developing targeted therapies that address the underlying pathophysiology of specific neurological conditions. Precision medicine approaches, including gene therapies, monoclonal antibodies, and small molecule inhibitors, are being explored to tailor treatments to individual patients' genetic and molecular profiles, potentially improving therapeutic outcomes and reducing treatment-related complications.
The primary market driver for Neurologic Disorders Therapeutics is the increasing disease burden and unmet medical needs associated with neurological disorders. Conditions such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis impose significant healthcare burdens globally, affecting millions of individuals and their families. Despite ongoing research efforts, many neurological disorders lack effective disease-modifying treatments, creating a substantial unmet need for innovative therapeutics. The growing prevalence of these conditions, coupled with the escalating societal and economic costs, drives the urgency for the development of novel and more efficacious therapies to address the complex challenges of neurological disorders.
An emerging opportunity in the Neurologic Disorders Therapeutics market lies in the repurposing of existing drugs for neurological indications. Drug repurposing, also known as drug repositioning, involves identifying new therapeutic uses for approved or investigational drugs beyond their original indications. With a better understanding of the molecular pathways underlying neurological disorders, there's growing interest in exploring the potential of existing drugs from other therapeutic areas for neurological applications. Repurposing offers several advantages, including reduced development timelines, lower costs, and a higher probability of success compared to de novo drug discovery. Collaborative efforts between academia, pharmaceutical companies, and regulatory agencies are essential to identify promising candidates and advance them through clinical development, potentially accelerating the availability of new treatment options for neurological disorders.
Alzheimer's Disease therapeutics represent a rapidly growing segment within Neurologic Disorders Therapeutics. With the increasing prevalence of Alzheimer's Disease globally and the lack of effective treatments to slow or halt its progression, there's a significant demand for novel therapeutics. Researchers are actively exploring various approaches, including immunomodulators, to target the underlying pathology of Alzheimer's, such as amyloid plaques and tau tangles. Immunomodulators hold promise in modulating the immune response to reduce neuroinflammation and potentially slow disease progression. Additionally, advancements in understanding the molecular mechanisms of Alzheimer's Disease have led to the development of innovative drugs targeting amyloid-beta and tau proteins, further driving growth in this segment. As the aging population continues to rise, the demand for effective treatments for Alzheimer's Disease is expected to fuel substantial growth in the market for Alzheimer's Disease therapeutics in the coming years.
By Indication
Multiple sclerosis
Alzheimer’s Disease
Parkinson’s Disease
Huntington’s Disease
Others
By DrugGlass
Immunomodulator
Interferons
Decarboxylase Inhibitors
Dopamine Agonists
Others
By Route of Administration
Oral
Injection
Transdermal
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
AbbVie Inc
Acadia Pharmaceuticals Inc
Acorda Therapeutics Inc
Bayer AG
Biogen Inc
Eisai Co. Ltd
F. Hoffmann La Roche Ltd
GlaxoSmithKline Plc
H Lundbeck AS
Johnson and Johnson
Merck KGaA
Mylan NV
Novartis AG
Otsuka Holdings Co. Ltd
Pfizer Inc
Sanofi S.A.
Takeda Pharmaceutical Co. Ltd
Teva Pharmaceutical Industries Ltd
UCB S.A.
USWM LLC
* List not Exhaustive
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Neurologic Disorders Therapeutics Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Neurologic Disorders Therapeutics Industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 Neurologic Disorders Therapeutics Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Neurologic Disorders Therapeutics Market Size Outlook, $ Million, 2021 to 2030
3.2 Neurologic Disorders Therapeutics Market Outlook by Type, $ Million, 2021 to 2030
3.3 Neurologic Disorders Therapeutics Market Outlook by Product, $ Million, 2021 to 2030
3.4 Neurologic Disorders Therapeutics Market Outlook by Application, $ Million, 2021 to 2030
3.5 Neurologic Disorders Therapeutics Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Neurologic Disorders Therapeutics Industry
4.2 Key Market Trends in Neurologic Disorders Therapeutics Industry
4.3 Potential Opportunities in Neurologic Disorders Therapeutics Industry
4.4 Key Challenges in Neurologic Disorders Therapeutics Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Neurologic Disorders Therapeutics Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Neurologic Disorders Therapeutics Market Outlook by Segments
7.1 Neurologic Disorders Therapeutics Market Outlook by Segments, $ Million, 2021- 2030
By Indication
Multiple sclerosis
Alzheimer’s Disease
Parkinson’s Disease
Huntington’s Disease
Others
By DrugGlass
Immunomodulator
Interferons
Decarboxylase Inhibitors
Dopamine Agonists
Others
By Route of Administration
Oral
Injection
Transdermal
8 North America Neurologic Disorders Therapeutics Market Analysis and Outlook To 2030
8.1 Introduction to North America Neurologic Disorders Therapeutics Markets in 2024
8.2 North America Neurologic Disorders Therapeutics Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Neurologic Disorders Therapeutics Market size Outlook by Segments, 2021-2030
By Indication
Multiple sclerosis
Alzheimer’s Disease
Parkinson’s Disease
Huntington’s Disease
Others
By DrugGlass
Immunomodulator
Interferons
Decarboxylase Inhibitors
Dopamine Agonists
Others
By Route of Administration
Oral
Injection
Transdermal
9 Europe Neurologic Disorders Therapeutics Market Analysis and Outlook To 2030
9.1 Introduction to Europe Neurologic Disorders Therapeutics Markets in 2024
9.2 Europe Neurologic Disorders Therapeutics Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Neurologic Disorders Therapeutics Market Size Outlook by Segments, 2021-2030
By Indication
Multiple sclerosis
Alzheimer’s Disease
Parkinson’s Disease
Huntington’s Disease
Others
By DrugGlass
Immunomodulator
Interferons
Decarboxylase Inhibitors
Dopamine Agonists
Others
By Route of Administration
Oral
Injection
Transdermal
10 Asia Pacific Neurologic Disorders Therapeutics Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Neurologic Disorders Therapeutics Markets in 2024
10.2 Asia Pacific Neurologic Disorders Therapeutics Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Neurologic Disorders Therapeutics Market size Outlook by Segments, 2021-2030
By Indication
Multiple sclerosis
Alzheimer’s Disease
Parkinson’s Disease
Huntington’s Disease
Others
By DrugGlass
Immunomodulator
Interferons
Decarboxylase Inhibitors
Dopamine Agonists
Others
By Route of Administration
Oral
Injection
Transdermal
11 South America Neurologic Disorders Therapeutics Market Analysis and Outlook To 2030
11.1 Introduction to South America Neurologic Disorders Therapeutics Markets in 2024
11.2 South America Neurologic Disorders Therapeutics Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Neurologic Disorders Therapeutics Market size Outlook by Segments, 2021-2030
By Indication
Multiple sclerosis
Alzheimer’s Disease
Parkinson’s Disease
Huntington’s Disease
Others
By DrugGlass
Immunomodulator
Interferons
Decarboxylase Inhibitors
Dopamine Agonists
Others
By Route of Administration
Oral
Injection
Transdermal
12 Middle East and Africa Neurologic Disorders Therapeutics Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Neurologic Disorders Therapeutics Markets in 2024
12.2 Middle East and Africa Neurologic Disorders Therapeutics Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Neurologic Disorders Therapeutics Market size Outlook by Segments, 2021-2030
By Indication
Multiple sclerosis
Alzheimer’s Disease
Parkinson’s Disease
Huntington’s Disease
Others
By DrugGlass
Immunomodulator
Interferons
Decarboxylase Inhibitors
Dopamine Agonists
Others
By Route of Administration
Oral
Injection
Transdermal
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
AbbVie Inc
Acadia Pharmaceuticals Inc
Acorda Therapeutics Inc
Bayer AG
Biogen Inc
Eisai Co. Ltd
F. Hoffmann La Roche Ltd
GlaxoSmithKline Plc
H Lundbeck AS
Johnson and Johnson
Merck KGaA
Mylan NV
Novartis AG
Otsuka Holdings Co. Ltd
Pfizer Inc
Sanofi S.A.
Takeda Pharmaceutical Co. Ltd
Teva Pharmaceutical Industries Ltd
UCB S.A.
USWM LLC
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Indication
Multiple sclerosis
Alzheimer’s Disease
Parkinson’s Disease
Huntington’s Disease
Others
By DrugGlass
Immunomodulator
Interferons
Decarboxylase Inhibitors
Dopamine Agonists
Others
By Route of Administration
Oral
Injection
Transdermal
The global Neurologic Disorders Therapeutics Market is one of the lucrative growth markets, poised to register a 5.1% growth (CAGR) between 2024 and 2030.
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.
AbbVie Inc, Acadia Pharmaceuticals Inc, Acorda Therapeutics Inc, Bayer AG, Biogen Inc, Eisai Co. Ltd, F. Hoffmann La Roche Ltd, GlaxoSmithKline Plc, H Lundbeck AS, Johnson and Johnson, Merck KGaA, Mylan NV, Novartis AG, Otsuka Holdings Co. Ltd, Pfizer Inc, Sanofi S.A., Takeda Pharmaceutical Co. Ltd, Teva Pharmaceutical Industries Ltd, UCB S.A., USWM LLC
Base Year- 2023; Estimated Year- 2024; Historic Period- 2018-2023; Forecast period- 2024 to 2030; Currency: USD; Volume